
Valvular regurgitation: What You Need to Know
Valvular regurgitation is when blood flows backward through the chambers of your heart. It can be mild and not cause symptoms, or it can be life threatening.
Your heart is a muscular organ that contains four chambers. Blood flows between these chambers and your lungs in a set pattern to distribute oxygen-containing blood to every organ in your body. Your heart also contains four valves that control blood flow through its chambers.
Valvular regurgitation occurs when blood moves backward through one of these valves. The severity depends largely on the amount of blood that backflows and whether or not it is causing symptoms or other problems.
Minor cases might not cause symptoms, whereas more severe cases may lead to issues such as shortness of breath or heartbeat abnormalities.
Read on to learn more about valvular regurgitation, including types, potential symptoms, and causes.
Types of valvular regurgitation
Valvular regurgitation is named after the valve through which blood backflows through. Types include:
Tricuspid valve regurgitation: Your tricuspid valve is found between your right atrium and right ventricle. Tricuspid valve regurgitation is characterized by the backflow of blood into your right atrium.
Pulmonary valve regurgitation: Your pulmonary valve separates your right ventricle from the blood vessels supplying your lungs. Regurgitation can cause blood to flow back into your right ventricle from these blood vessels.
Mitral valve regurgitation: Your mitral valve is found between your left atrium and left ventricle. Mitral valve regurgitation is characterized by the backflow of blood into your left atrium.
Aortic valve regurgitation: The aortic valve is found between your left ventricle and your aorta, the large blood vessel that carries blood away from your heart. Aortic valve regurgitation causes blood to flow back into your left ventricle from your aorta.
The most common type is mitral valvular regurgitation.
What are the symptoms of valvular regurgitation?
Symptoms of valvular regurgitation can range from non-apparent to severe. If your condition is caused by another condition, such as heart failure, your symptoms may get progressively worse over time.
Symptoms may include:
irregular heartbeat (arrhythmia)
shortness of breath, which might be worse when lying flat
new or worsening heart palpitations, which can cause heart:
pounding
fluttering
whooshing
swelling around your feet or ankles
coughing
feeling faint
fatigue
chest pain
It's important to see your doctor if you experience any of these symptoms. Severe cases can lead to complications such as:
heart failure
arrhythmia (irregular heart rhythm)
sudden cardiac arrest
blood clots
stroke
pulmonary hypertension
What are the causes of valvular regurgitation?
Valvular regurgitation can develop due to congenital heart problems present from birth or develop secondary to other conditions affecting your heart.
Tricuspid valve regurgitation: In adults, tricuspid regurgitation is usually secondary to other heart problems, such as cardiomyopathies. Cardiomyopathy is a disease of your heart muscle, and coronary artery disease is when plaque builds up in the blood vessels in your heart and restricts blood flow.
Pulmonary valve regurgitation: The leading causes of pulmonary valve regurgitation in adults are pulmonary hypertension or congenital heart defects. Pulmonary hypertension is high blood pressure in the blood vessels connecting your heart and lungs.
Mitral valve regurgitation: Primary mitral valve regurgitation can develop due to congenital heart defects, infections, and complications such as rheumatic heart disease, or connective tissue disorders such as Marfan syndrome or lupus. Secondary mitral valve regurgitation can develop due to conditions such as congestive heart failure or atrial fibrillation.
Aortic valve disease: The two most common causes of aortic regurgitation are dilated aorta and bicuspid aortic valve. Calcified aortic stenosis is when your aortic valve thickens and narrows due to calcium buildup.
How is valvular regurgitation treated?
The treatment for valvular regurgitation depends on the underlying cause and severity. Mild cases might not need any treatment, but your doctor may still want to follow up regularly to ensure your condition doesn't progress.
More severe cases may require medications or surgery to prevent and manage complications and symptoms.
Medications
Doctors may prescribe people with valvular heart disease many types of medications, such as the following:
angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers to open your blood vessels
anti-arrhythmic medications to restore your heart rhythm
antibiotics to prevent infections
anticoagulants to reduce the risk of blood clots
beta-blockers to help your heart beat slower
diuretics to reduce the amount of fluid in your body
vasodilators to reduce your heart's workload
Surgery
Severe cases of valvular regurgitation may require valve repair or valve replacement. These procedures may be performed through open-heart surgery or minimally invasive procedures, where your surgeon makes the repair or replacement through a small incision and special tools.
These noninvasive procedures are catheter-based therapies. A cardiologist inserts the catheter into the blood vessels to reach the heart.
Learn more about valve replacement surgery.
Frequently asked questions
Here are some frequently asked questions people have about valve regurgitation.
What is meant by valve regurgitation?
Valvular regurgitation is when a valve in your heart doesn't close completely, and blood flows backward into one of the chambers of your heart. It can also occur if blood flows back from the blood vessels leaving the heart, such as the aorta or pulmonary artery, back into the heart.
Valvular regurgitation is when a valve in your heart doesn't close completely, and blood flows backward into one of the chambers of your heart. It can also occur if blood flows back from the blood vessels leaving the heart, such as the aorta or pulmonary artery, back into the heart.
What is the life expectancy of a person with valvular regurgitation?
The life expectancy for people with valvular regurgitation depends on factors such as the severity and other medical conditions.
The life expectancy for people with valvular regurgitation depends on factors such as the severity and other medical conditions.
How serious is valve regurgitation?
If valve regurgitation is left untreated, it can be a serious problem, potentially leading to heart failure. It's important to seek medical attention if you suspect you may have heart valve regurgitation and follow up with any recommended treatment plans and tests.
If valve regurgitation is left untreated, it can be a serious problem, potentially leading to heart failure. It's important to seek medical attention if you suspect you may have heart valve regurgitation and follow up with any recommended treatment plans and tests.
Takeaway
Valvular regurgitation is the backflow of blood through one of the valves in your heart. Mild cases might not be of concern or cause symptoms. More severe cases can cause serious symptoms that may be life threatening.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
21 minutes ago
- Forbes
The U.S. Government Is Stuck With SpaceX. But Trump Can Still Hurt It.
Donald Trump and Elon Musk arrive for a test launch of SpaceX's Starship rocket on November 19, 2024, in Brownsville, Texas. In the barrage of attacks that President Donald Trump and Elon Musk fired at each other Thursday, one stood out: Trump's threat to cancel federal contracts with companies owned by the world's richest man. The primary target: SpaceX, which has received at least $21 billion in government contracts, with about $13 billion still outstanding. Musk probably doesn't have much to fear. Legally, the Trump administration would likely enmire itself in lengthy legal disputes if it appeared to cancel contracts out of spite. Moreover, as the world's No. 1 launch provider and maker of low-Earth orbit satellites, SpaceX may have made itself indispensable. 'The [U.S. government] is simply too locked in to cut them off over a social media meltdown,' said Kimberly Siversen Burke, director of government affairs at the consultancy Quilty Space. Nonetheless, there are some types of contracts that could be vulnerable for cancellation, and ways the government could lessen its dependence on SpaceX going forward. The 134 rockets SpaceX launched last year accounted for 83% of all satellites put into orbit worldwide. With its reliable, partially reusable Falcon 9, the company has come to dominate U.S. national security launches. Its chief competitor, United Launch Alliance, a joint venture of Boeing and Lockheed Martin, has struggled to keep up, with multiyear delays in developing its new Vulcan rocket. The U.S. government may have more options to carry its military satellites to space going forward. Vulcan is now operational and Blue Origin, the space company founded by Musk's billionaire rival Jeff Bezos, pulled off a successful first launch of its New Glenn rocket in January. In the latest round of contracts awarded by Space Force, SpaceX won 28 launches from 2027 through 2032, a little more than half, with ULA getting 19 and Blue Origin seven. But ULA and Blue Origin have their hands full scaling up, said Todd Harrison, a defense and space analyst with the American Enterprise Institute. 'There's no replacing SpaceX. You just do not have the capacity in our other launch options.' SpaceX has also become a major supplier of national security satellites. The National Reconnaissance Office is depending on SpaceX to build out a multibillion-dollar network of hundreds of spy satellites in low-Earth orbit based on the company's Starshield platform. For delivering cargo and astronauts to the International Space Station, NASA has also had to rely on SpaceX, as Boeing has struggled to fix defects in its Starliner spacecraft. But there are some relatively small-dollar SpaceX contracts that could be vulnerable, said Burke. The government could lower its exposure to SpaceX by looking for early phase development programs that don't have a contractor locked in yet. For example, SpaceX has won roughly $140 million in contracts on an Air Force program to test whether commercial satellite services can be integrated into tactical military communications, Burke said. Another way Trump could hurt Musk, as well as Ukraine, would be to cancel or reduce a $537 million contract to provide Starlink satellite communications services to the Ukrainian military. But rather than targeting existing contracts, where the administration could make a greater impact is by steering new business to others and reorienting its plans. The Commerce Department could backtrack on a revamp announced in March to a $42 billion program to expand rural broadband access that was expected to make Starlink eligible to compete for grants. Till now the program has only included telecom companies laying fiber-optic cables. Trump could also pull back from the support he promised in his inaugural address for Musk's ultimate ambition: to reach Mars. 'Where Trump can single handedly harm SpaceX in a significant way is redirecting the mission goals for NASA,' Harrison said. Given how mercurial Musk has proven to be, perhaps diversifying away from SpaceX isn't a bad idea. Burke worries, however, that the bad blood will undo years of work to convince the Pentagon and other national security agencies that they can rely on any commercial companies. 'Elon's antics are threatening to rewind the tape,' she said. MORE FROM FORBES


Associated Press
22 minutes ago
- Associated Press
101 dogs living in packed, filthy conditions removed from North Carolina home
RALEIGH, N.C. (AP) — Dozens of dogs found living in packed, filthy conditions were removed from a North Carolina home. Animal control officers responding to a complaint in Raleigh County discovered 101 dogs crammed in stacked cages or roaming in confined quarters at the home on Wednesday, the Wake County Society for the Prevention of Cruelty to Animals said on Facebook. Many of the dogs were small breeds. Among those rescued were several puppies and older dogs. The homeowner agreed to relinquish the dogs, along with 21 chickens, news outlets reported. The dogs were taken in by eight different shelters and were undergoing medical assessments, the SPCA chapter said. Many dogs had matted fur as well as skin and dental issues. It wasn't known whether the homeowner faces charges. A telephone call to the Raleigh police department wasn't immediately returned Friday. On Friday, the chapter said that several dogs under its care were 'getting the spa day of their lives — and their first taste of fresh air, possibly ever. We're seeing a lot of smiles from these guys. 'This is the biggest moment in these dogs' lives, and we are feeling so grateful to be a part of their healing.'


Forbes
26 minutes ago
- Forbes
How AI Is Helping Cancer Patients: Saving Lives And Money
Medical technology concept. Medical doctor. getty Cancer treatment is costly. The average cost of cancer care in the U.S. is around $150,000 per patient—more than four times the cost of treatment for other common health conditions, according to AARP. The American Cancer Society projected that In 2025, more than 2 million people in the U.S. are expected to be diagnosed with cancer, with over 618,000 deaths projected. With these high costs, artificial intelligence (AI) is offering new solutions that are not only saving lives but also making cancer care more affordable. Early detection is one of the most effective ways to reduce cancer treatment costs. When cancer is caught in its earliest stages, treatments tend to be less aggressive and more affordable. At The Christ Hospital, AI has significantly improved lung cancer detection. 'Nearly 70% of lung cancer cases are now found at stage I or II, well above the national average of 46%,' said Seth Howard, executive vice president of research and development at Epic. 'In just six months, over 60 patients started treatment earlier, significantly improving their chances of survival.' By diagnosing cancer earlier, AI allows doctors to offer more cost-effective treatment options, which helps lower the financial burden on both patients and healthcare systems. ArteraAI is another example of how AI is transforming cancer care. Their AI technology is helping doctors determine which cancer treatments are best for their patients, preventing unnecessary therapies. 'AI is the most transformative tech we've had in a long time,' said Andre, founder of Artera. 'The impact AI has had on the healthcare system is as powerful as computers have had on the healthcare system. With the ArteraAI Prostate Test, we can personalize treatments, reducing unnecessary costs while improving outcomes.' The ArteraAI Prostate Test is fully reimbursed by Medicare under its established payment rate, meaning no out-of-pocket costs for eligible Medicare patients. This makes prostate cancer care more affordable and reduces financial strain during treatment. Surgery is often a key part of cancer treatment. Proprio, a company that has developed AI-powered surgical technology, provides surgeons with real-time data during operations, reducing the need for traditional imaging like CT scans and X-rays. This technology allows for faster surgeries, less strain on hospital staff, and quicker recovery times, which ultimately lowers the cost of care for patients. Another breakthrough demonstrating AI's transformative potential in cancer care is AION Biosystems' TempShield device. A recent study showed that TempShield, an AI-powered wearable thermometer for oncology patients, can reduce mortality rates by an astonishing 90% among cancer patients undergoing chemotherapy and inpatient hospital stays by 79%. This innovation addresses a crucial, yet often overlooked, fact: more than 50% of cancer deaths are preventable because they result from infections like pneumonia rather than cancer itself. If you spot a temperature spike (and hence an infection) early and treat it, you save lives. TempShield's continuous temperature monitoring provides clinicians with alerts up to 72 hours before symptoms of infection appear, enabling earlier intervention. 'The real danger in cancer care isn't just the disease—it's the complications we miss,' said Sam Barend, CEO of AION Biosystems. 'TempShield is a game-changer: small, simple, and affordable, and it's helping save lives by catching infections before symptoms appear—just like the blood glucose monitor did for diabetes.' AI is revolutionizing cancer care, not only improving outcomes but also making treatment more affordable. Early detection, personalized treatment, and more efficient surgeries all contribute to lowering the financial burden on patients while providing better care. With innovations like the ArteraAI Prostate Test and TempShield, AI is making cancer care smarter, more accessible, and more cost-effective for patients across the globe. As AI technologies continue to evolve, they will undoubtedly play an even greater role in both saving lives and reducing the financial strain of cancer treatment.